1. Home
  2. JBLU vs VRDN Comparison

JBLU vs VRDN Comparison

Compare JBLU & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JetBlue Airways Corporation

JBLU

JetBlue Airways Corporation

HOLD

Current Price

$5.26

Market Cap

2.1B

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$19.24

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBLU
VRDN
Founded
1998
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Air Freight/Delivery Services
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
JBLU
VRDN
Price
$5.26
$19.24
Analyst Decision
Sell
Strong Buy
Analyst Count
13
14
Target Price
$4.91
$35.46
AVG Volume (30 Days)
29.6M
2.3M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
27.83
N/A
EPS
N/A
N/A
Revenue
$9,062,000,000.00
$5,706,000.00
Revenue This Year
$12.11
$13.73
Revenue Next Year
$6.75
$279.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.87
$13.18
52 Week High
$6.46
$34.29

Technical Indicators

Market Signals
Indicator
JBLU
VRDN
Relative Strength Index (RSI) 45.64 55.54
Support Level $4.54 $17.54
Resistance Level $6.31 $20.44
Average True Range (ATR) 0.30 0.84
MACD -0.09 -0.08
Stochastic Oscillator 33.67 47.01

Price Performance

Historical Comparison
JBLU
VRDN

About JBLU JetBlue Airways Corporation

JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: